SOURCE-LINKED STUDY SUMMARY
Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB).
Abstract summarizedQuality not appraised
- What was studied
- A double-blind phase 2 study tested zervimesine safety and exploratory efficacy in Lewy body dementia.
- Who / model studied
- 130 randomized adults aged 50–85 with probable mild-to-moderate Lewy body dementia; 109 completed the study.
- Studied dose & schedule
- Zervimesine 100 mg, 300 mg or placebo over 26 weeks.
- What the study found
- Exploratory outcomes showed favorable trends. Adverse-event discontinuations were 4.5% with 100 mg, 16.3% with 300 mg and 4.8% with placebo.
- Limitations & context
- Exploratory efficacy requires larger confirmatory trials. Findings do not establish dementia reversal, Alzheimer’s efficacy or healthy-person cognitive enhancement.
Read summary source ↗ · Prepared 9/24/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1002/alz.71004